| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Allophycocyanin | NB7446APC | |||
| Biotin | NB7446B | |||
| DyLight 350 | NB7446UV | |||
| DyLight 405 | NB7446V | |||
| DyLight 488 | NB7446G | |||
| DyLight 550 | NB7446R | |||
| DyLight 594 | NB7446DL594 | |||
| DyLight 650 | NB7446C | |||
| DyLight 680 | NB7446FR | |||
| DyLight 755 | NB7446IR | |||
| FITC | NB7448 | |||
| HRP | NB7449 | |||
| Janelia Fluor 525 | NB7446JF525 | |||
| Janelia Fluor 669 | NB7446JF669 | |||
| PE | NB7446PE | |||
| PerCP | NB7446PCP | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Allophycocyanin | NB7558APC | |||
| Biotin | NB7558B | |||
| DyLight 350 | NB7558UV | |||
| DyLight 405 | NB7558V | |||
| DyLight 488 | NB7558G | |||
| DyLight 550 | NB7558R | |||
| DyLight 594 | NB7558DL594 | |||
| DyLight 650 | NB7558C | |||
| DyLight 680 | NB7558FR | |||
| DyLight 755 | NB7558IR | |||
| FITC | NB7560 | |||
| HRP | NB7561 | |||
| Janelia Fluor 525 | NB7558JF525 | |||
| Janelia Fluor 669 | NB7558JF669 | |||
| PE | NB7558PE | |||
| PerCP | NB7558PCP | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alkaline Phosphatase | NBP1-74975 | |||
| Biotin | NBP1-74976 | |||
| DyLight 488 | NBP1-74980 | |||
| DyLight 550 | NBP1-75816 | |||
| DyLight 594 | NBP1-75817 | |||
| DyLight 633 | NBP1-75818 | |||
| FITC | NBP1-74977 | |||
| HRP | NBP1-74978 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Pre-adsorbed | NBP1-74990 | |||
| Pre-adsorbed | NBP1-74992 | |||
| Pre-adsorbed | NBP1-74988-0.5mg | |||
| Pre-adsorbed | NBP1-74988JF549 | |||
| Pre-adsorbed | NBP1-74988JF646 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Pre-adsorbed | NBP1-75003 | |||
| Pre-adsorbed | NBP1-75004 | |||
| Pre-adsorbed | NBP1-75005 | |||
| Pre-adsorbed | NBP1-75006 | |||
| Pre-adsorbed | NBP1-75851 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Pre-adsorbed | NBP1-74996 | |||
| Pre-adsorbed | NBP1-74997 | |||
| Pre-adsorbed | NBP1-74999 | |||
| Pre-adsorbed | NBP1-74995-0.5mg | |||
| Pre-adsorbed | NBP1-74995JF549 | |||
| Pre-adsorbed | NBP1-74995JF646 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Pre-adsorbed | NBP1-74982 | |||
| Pre-adsorbed | NBP1-74983 | |||
| Pre-adsorbed | NBP1-74984 | |||
| Pre-adsorbed | NBP1-74985 | |||
| Pre-adsorbed | NBP1-75827 | |||
| Pre-adsorbed | NBP1-74981-0.5mg | |||
| Pre-adsorbed | NBP1-74981JF549 | |||
| Pre-adsorbed | NBP1-74981JF646 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Pre-adsorbed | NBP1-74861 | |||
| Pre-adsorbed | NBP1-74862 | |||
| Pre-adsorbed | NBP1-74864 | |||
| Pre-adsorbed | NBP1-74860-0.5mg | |||
| Pre-adsorbed | NBP1-74860JF549 | |||
| Pre-adsorbed | NBP1-74860JF646 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Pre-adsorbed | NBP1-74981 | |||
| Pre-adsorbed | NBP1-74982 | |||
| Pre-adsorbed | NBP1-74983 | |||
| Pre-adsorbed | NBP1-74984 | |||
| Pre-adsorbed | NBP1-74985 | |||
| Pre-adsorbed | NBP1-75827 | |||
| Pre-adsorbed | NBP1-74981-0.5mg | |||
| Pre-adsorbed | NBP1-74981JF549 | |||
| Pre-adsorbed | NBP1-74981JF646 | |||
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - A) Kidney from control did not show any specific staining in the glomeruli. Only erythrocytes (arrow) showed weak fluorescence. B) 1 day: endothelium & material within the capillaries of a glomerulus were highly fluorescent (white arrow). In an adjacent glomerulus, only the endothelium was stained (white arrowhead) not for the lumina of the vessels (black arrow). C) Erythrocytes (arrowhead) and endothelium (arrow). D) 7 days: fluorescence within the capillaries (arrowhead) & endothelium was weaker. E) 1 day after ranibizumab injection, the endothelium cell layer (white arrow) and erythrocytes (arrowhead and black arrow) were fluorescent. F) The fluorescence (arrowhead) was nearly lost 7 days after injection. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0113701) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Goat-anti-Human-IgG-Fc-fragment-Secondary-Antibody-Immunohistochemistry-NB7446-img0002.jpg "Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - A) Kidney from control did not show any specific staining in the glomeruli. Only erythrocytes (arrow) showed weak fluorescence. B) 1 day: endothelium & material within the capillaries of a glomerulus were highly fluorescent (white arrow). In an adjacent glomerulus, only the endothelium was stained (white arrowhead) not for the lumina of the vessels (black arrow). C) Erythrocytes (arrowhead) and endothelium (arrow). D) 7 days: fluorescence within the capillaries (arrowhead) & endothelium was weaker. E) 1 day after ranibizumab injection, the endothelium cell layer (white arrow) and erythrocytes (arrowhead and black arrow) were fluorescent. F) The fluorescence (arrowhead) was nearly lost 7 days after injection. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0113701) licensed under a CC-BY license.")
![Western Blot: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Image from verified customer review. Image using the HRP form of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Human-IgG-Fc-Secondary-Antibody-Western-Blot-NB7446-img0001.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416154644.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416165644.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416154630.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416175295.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416163732.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416171447.jpg)
![Western Blot: Goat anti-Mouse IgG Fc Secondary Antibody [NB7558] - Analysis of Cadherin in Huh7 cell lysate. Image from verified customer review. Image using the HRP form of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Mouse-IgG-Fc-Secondary-Antibody-Western-Blot-NB7558-img0001.jpg "Western Blot: Goat anti-Mouse IgG Fc Secondary Antibody [NB7558] - Analysis of Cadherin in Huh7 cell lysate. Image from verified customer review. Image using the HRP form of this antibody.")
![Immunocytochemistry/Immunofluorescence: Goat anti-Human IgG Fc Secondary Antibody [NBP1-74974] - SKBR3 human breast cancer cell line. Image from verified customer review. Analysis using the DyLight-550 conjugated antibody.](http://images.novusbio.com/fullsize/Goat-anti-Human-IgG-Fc-fragment-Secondary-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-74974-img0003.jpg "Immunocytochemistry/Immunofluorescence: Goat anti-Human IgG Fc Secondary Antibody [NBP1-74974] - SKBR3 human breast cancer cell line. Image from verified customer review. Analysis using the DyLight-550 conjugated antibody.")
![Immunocytochemistry/Immunofluorescence: Goat anti-Human IgG Fc Secondary Antibody [NBP1-74974] - MCF7 human breast cancer cell line. Image from verified customer review.](http://images.novusbio.com/fullsize/Goat-anti-Human-IgG-Fc-fragment-Secondary-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-74974-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: Goat anti-Human IgG Fc Secondary Antibody [NBP1-74974] - SKBR3 human breast cancer cell line. Image from verified customer review.](http://images.novusbio.com/fullsize/Goat-anti-Human-IgG-Fc-fragment-Secondary-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-74974-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: Goat anti-Mouse IgG Fc Secondary Antibody [NBP2-60664] - Image from the DyLight 488 version of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Mouse-IgG-Fc-Secondary-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-60664-img0006.jpg "Immunocytochemistry/Immunofluorescence: Goat anti-Mouse IgG Fc Secondary Antibody [NBP2-60664] - Image from the DyLight 488 version of this antibody.")
![Immunocytochemistry/Immunofluorescence: Goat anti-Mouse IgG Fc Secondary Antibody [NBP2-60664] - Analysis of Vero cells. Cells were fixed in 4% paraformaldehyde for 20 minutes at room temperature. Image from verified customer review. Image using the DyLight 488 form of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Mouse-IgG-Fc-Secondary-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-60664-img0005.jpg)
![Fluorophore-linked immunosorbent assay: Goat anti-Mouse IgG Fc Secondary Antibody [NBP2-60664] - Image using the DyLight 405 form of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Mouse-IgG-Fc-Secondary-Antibody-Fluorophore-linked-immunosorbent-assay-NBP2-60664-img0001.jpg)
![Fluorophore-linked immunosorbent assay: Goat anti-Mouse IgG Fc Secondary Antibody [NBP2-60664] - Image using the DyLight 488 form of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Mouse-IgG-Fc-Secondary-Antibody-Fluorophore-linked-immunosorbent-assay-NBP2-60664-img0002.jpg)
![Fluorophore-linked immunosorbent assay: Goat anti-Mouse IgG Fc Secondary Antibody [NBP2-60664] - Image using the DyLight 680 form of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Mouse-IgG-Fc-Secondary-Antibody-Fluorophore-linked-immunosorbent-assay-NBP2-60664-img0003.jpg)
![Fluorophore-linked immunosorbent assay: Goat anti-Mouse IgG Fc Secondary Antibody [NBP2-60664] - Image using the DyLight 800 form of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Mouse-IgG-Fc-Secondary-Antibody-Fluorophore-linked-immunosorbent-assay-NBP2-60664-img0004.jpg)
![ELISA: Goat anti-Mouse IgG Fc Secondary Antibody [NBP2-60664] - ELISA results of Goat anti-Mouse IgG Fc Secondary antibodyy tested against purified MouseIgG Fc protein. Each well was coated in duplicate with 1.0 ug of MouseIgG Fc. The starting dilution of antibody was 5ug/ml and the X-axis represents the Log10 of a 3-fold dilution. This titration is a 4-parameter curve fit where the IC50 is defined as the titer of the antibody. Assay performed using 3% fish gelatin as blocking buffer, Donkey anti-Goat IgG Antibody Peroxidase Conjugated (Min X Ch GP Ham Hs Ms Rb & Rt Serum Proteins) and TMB substrate.](http://images.novusbio.com/fullsize/Goat-anti-Mouse-IgG-Fc-Secondary-Antibody-ELISA-NBP2-60664-img0009.jpg)
![Western Blot: Goat anti-Rabbit IgG Fc Secondary Antibody [NBP2-60661] - Western Blot of Goat anti-Rabbit IgG Fc Secondary antibody.Lane 1: Rabbit F(c).Load: 50 ng per lane.Primary antibody: Rabbit F(c) antibody at 1:1,000 overnight at 4C.Secondary antibody: DyLight(TM) 649 goat secondary antibody at 1:20,000 for 30 min at RT.Blocking buffer for 30 min at RT.Predicted/Observed size: 25 kDa, 25 kDa for Rabbit F(c).](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-Fc-Secondary-Antibody-Western-Blot-NBP2-60661-img0013.jpg "Western Blot: Goat anti-Rabbit IgG Fc Secondary Antibody [NBP2-60661] - Western Blot of Goat anti-Rabbit IgG Fc Secondary antibody.Lane 1: Rabbit F(c).Load: 50 ng per lane.Primary antibody: Rabbit F(c) antibody at 1:1,000 overnight at 4C.Secondary antibody: DyLight(TM) 649 goat secondary antibody at 1:20,000 for 30 min at RT.Blocking buffer for 30 min at RT.Predicted/Observed size: 25 kDa, 25 kDa for Rabbit F(c).")
![Immunocytochemistry/Immunofluorescence: Goat anti-Rabbit IgG Fc Secondary Antibody [NBP2-60661] - Immunocytochemistry/Immunofluorescence: [DyLight 488] [NBP1-72943]](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-Fc-Secondary-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-60661-img0007.jpg)
![Western Blot: Goat anti-Rabbit IgG Fc Secondary Antibody [NBP2-60661] - Lane 1: Rabbit IgG whole molecule. Lane 2: Rabbit IgG F(ab) Fragment. Lane 3: Rabbit IgG F(c) Fragment. Lane 4: Rabbit IgM Whole Molecule. Lane 5: Normal Rabbit Serum. All samples were reduced. Load: 50 ng of IgG, F(ab), IgM and Serum, 100 ng of F(c). Block: incubated with blocking buffer for 30 min at RT. Primary Antibody: Anti-Rabbit IgG F(c) (GOAT) Antibody 1:2,000 for 60 min at RT. Secondary antibody: Anti-Goat IgG (DONKEY) Peroxidase Conjugated Antibody 1:40,000 in incubated with blocking buffer for 30 min at RT. Predicted/Observed Size: 25 and 50 kDa for Rabbit IgG and Serum, 25 kDa for F(c) and F(ab), 70 and 23 kDa for IgM. Rabbit F(c) migrates slightly higher. Image using the Rhodamine form of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-Fc-Secondary-Antibody-Western-Blot-NBP2-60661-img0005.jpg)
![Fluorophore-linked immunosorbent assay: Goat anti-Rabbit IgG Fc Secondary Antibody [NBP2-60661] - Fluorophore-linked immunosorbent assay: Image using the DyLight 405 format of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-Fc-Secondary-Antibody-Fluorophore-linked-immunosorbent-assay-NBP2-60661-img0008.jpg)
![Fluorophore-linked immunosorbent assay: Goat anti-Rabbit IgG Fc Secondary Antibody [NBP2-60661] - Image using the DyLight 488 format of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-Fc-Secondary-Antibody-Fluorophore-linked-immunosorbent-assay-NBP2-60661-img0009.jpg)
![Fluorophore-linked immunosorbent assay: Goat anti-Rabbit IgG Fc Secondary Antibody [NBP2-60661] - Image using the DyLight 680 format of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-Fc-Secondary-Antibody-Fluorophore-linked-immunosorbent-assay-NBP2-60661-img0010.jpg)
![Fluorophore-linked immunosorbent assay: Goat anti-Rabbit IgG Fc Secondary Antibody [NBP2-60661] - Image using the DyLight 800 format of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-Fc-Secondary-Antibody-Fluorophore-linked-immunosorbent-assay-NBP2-60661-img0011.jpg)